Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post $19.72 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Oxford Immunotec Global’s earnings, with the lowest sales estimate coming in at $14.63 million and the highest estimate coming in at $28.51 million. Oxford Immunotec Global posted sales of $25.03 million during the same quarter last year, which suggests a negative year-over-year growth rate of 21.2%. The company is expected to announce its next quarterly earnings results on Tuesday, February 26th.
On average, analysts expect that Oxford Immunotec Global will report full year sales of $97.56 million for the current financial year, with estimates ranging from $81.38 million to $111.90 million. For the next year, analysts anticipate that the firm will post sales of $88.37 million, with estimates ranging from $67.25 million to $125.09 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Oxford Immunotec Global.
Oxford Immunotec Global (NASDAQ:OXFD) last posted its earnings results on Friday, November 9th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative return on equity of 41.15% and a negative net margin of 12.51%. The firm had revenue of $16.10 million for the quarter, compared to the consensus estimate of $33.60 million. During the same period in the prior year, the business earned ($0.70) EPS. Oxford Immunotec Global’s quarterly revenue was up 7.3% compared to the same quarter last year.
Shares of Oxford Immunotec Global stock traded down $0.43 during mid-day trading on Tuesday, hitting $13.93. 66,860 shares of the stock were exchanged, compared to its average volume of 98,099. Oxford Immunotec Global has a 12 month low of $10.00 and a 12 month high of $19.19. The stock has a market cap of $367.21 million, a P/E ratio of -10.24 and a beta of -0.10.
In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 86,100 shares of Oxford Immunotec Global stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the transaction, the chief executive officer now owns 539,569 shares of the company’s stock, valued at approximately $9,938,860.98. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $15.50, for a total transaction of $46,500.00. Following the completion of the sale, the director now directly owns 9,000 shares in the company, valued at approximately $139,500. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,100 shares of company stock worth $1,966,662. Insiders own 6.61% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. First Light Asset Management LLC raised its holdings in shares of Oxford Immunotec Global by 28.5% in the 3rd quarter. First Light Asset Management LLC now owns 1,594,009 shares of the company’s stock worth $25,871,000 after purchasing an additional 353,618 shares during the period. BlackRock Inc. raised its holdings in shares of Oxford Immunotec Global by 2.4% in the 3rd quarter. BlackRock Inc. now owns 1,310,098 shares of the company’s stock worth $21,264,000 after purchasing an additional 30,774 shares during the period. Granahan Investment Management Inc. MA raised its holdings in shares of Oxford Immunotec Global by 9.1% in the 2nd quarter. Granahan Investment Management Inc. MA now owns 565,332 shares of the company’s stock worth $7,287,000 after purchasing an additional 47,159 shares during the period. Penn Capital Management Co. Inc. raised its holdings in shares of Oxford Immunotec Global by 5.5% in the 3rd quarter. Penn Capital Management Co. Inc. now owns 271,280 shares of the company’s stock worth $4,403,000 after purchasing an additional 14,254 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Oxford Immunotec Global by 3.1% in the 2nd quarter. Northern Trust Corp now owns 265,487 shares of the company’s stock worth $3,423,000 after purchasing an additional 7,862 shares during the period. 90.94% of the stock is currently owned by institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.
Featured Article: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.